30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Iterum Therapeutics PLC (ITRM)

Track

Stock chart
Ticker: ITRM Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Dunne Michael W.
1 purchase — total 2,191 USD
Buy 18 Nov 2025
Value US$4,110,547.27 | Price 230.72 | Shares 80,647
Buy 8 Aug 2025
Value US$1,755,499.61 | Price 143.50 | Shares 67,223
Buy 22 Dec 2023
Value US$35,000.00 | Price 1.40 | Shares 25,000
Buy 18 Dec 2023
Value US$18,442.00 | Price 1.84 | Shares 10,000
Buy 22 Nov 2023
Value US$40,690.00 | Price 2.03 | Shares 20,000
Buy 20 Nov 2023
Value US$15,863.00 | Price 1.59 | Shares 10,000
Sale 2 Dec 2022
Value US$4,441.80 | Price 1.32 | Shares 3,365
Sale 20 Sep 2022
Value US$12,910.20 | Price 1.78 | Shares 7,246
Sale 19 Sep 2022
Value US$26,478.00 | Price 1.77 | Shares 15,000
Sale 16 Sep 2022
Value US$28,542.00 | Price 1.90 | Shares 15,000
Sale 15 Sep 2022
Value US$30,271.50 | Price 2.02 | Shares 15,000
Sale 14 Sep 2022
Value US$31,456.50 | Price 2.10 | Shares 15,000
Sale 13 Sep 2022
Value US$32,118.00 | Price 2.14 | Shares 15,000
Sale 12 Sep 2022
Value US$34,608.00 | Price 2.31 | Shares 15,000
Sale 9 Sep 2022
Value US$34,729.50 | Price 2.32 | Shares 15,000
Sale 8 Sep 2022
Value US$7,465.02 | Price 2.26 | Shares 3,298
Buy 7 Sep 2022
Value US$22,200.00 | Price 2.22 | Shares 10,000
Sale 14 Mar 2022
Value US$17,910.16 | Price 0.38 | Shares 47,132
Sale 12 Feb 2021
Value US$24,107,284.23 | Price 2.27 | Shares 10,619,949
Sale 11 Feb 2021
Value US$25,900,000.00 | Price 2.59 | Shares 10,000,000
Sale 26 Jan 2021
Value US$147,819.85 | Price 1.73 | Shares 85,445
Sale 26 Jan 2021
Value US$57,337.39 | Price 1.73 | Shares 33,143
Sale 26 Jan 2021
Value US$58,591.64 | Price 1.73 | Shares 33,868
Buy 27 Oct 2020
Value US$0.00 | Price 0.00 | Shares 61,540
Planned sale 30 Sep 2020
Value US$92,053.20 | Price 1.64 | Shares 56,130
Sale 2 Jun 2020
Value US$642,960.00 | Price 1.61 | Shares 400,000
Sale 1 Jun 2020
Value US$169,120.00 | Price 1.69 | Shares 100,000
Buy 30 Nov 2018
Value US$62,887.00 | Price 6.29 | Shares 10,000
Buy 30 Oct 2018
Value US$353,800.00 | Price 6.10 | Shares 58,000
Buy 4 Sep 2018
Value US$5,000.00 | Price 10.00 | Shares 500
Buy 27 Aug 2018
Value US$5,000.00 | Price 10.00 | Shares 500
Buy 24 Aug 2018
Value US$5,000.00 | Price 10.00 | Shares 500
Buy 23 Aug 2018
Value US$5,218.70 | Price 10.44 | Shares 500
Buy 17 Aug 2018
Value US$17,465.60 | Price 8.73 | Shares 2,000
Buy 30 May 2018
Value US$4,388,878.00 | Price 13.00 | Shares 337,606
Buy 30 May 2018
Value US$4,999,995.00 | Price 13.00 | Shares 384,615
Buy 30 May 2018
Value US$3,614,806.00 | Price 13.00 | Shares 278,062
Buy 30 May 2018
Value US$4,999,995.00 | Price 13.00 | Shares 384,615
Buy 30 May 2018
Value US$3,614,806.00 | Price 13.00 | Shares 278,062
Buy 30 May 2018
Value US$39,000.00 | Price 13.00 | Shares 3,000
Buy 30 May 2018
Value US$6,586,528.00 | Price 13.00 | Shares 506,656
Buy 30 May 2018
Value US$52,000.00 | Price 13.00 | Shares 4,000
Buy 30 May 2018
Value US$6,586,528.00 | Price 13.00 | Shares 506,656
Buy 30 May 2018
Value US$2,974,920.00 | Price 13.00 | Shares 228,840
Buy 30 May 2018
Value US$105,872.00 | Price 13.00 | Shares 8,144
Buy 30 May 2018
Value US$1,314,950.00 | Price 13.00 | Shares 101,150
Buy 30 May 2018
Value US$4,614,337.00 | Price 13.00 | Shares 354,949
Buy 30 May 2018
Value US$26,000.00 | Price 13.00 | Shares 2,000
Buy 30 May 2018
Value US$6,500,000.00 | Price 13.00 | Shares 500,000
Buy 30 May 2018
Value US$6,500,000.00 | Price 13.00 | Shares 500,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-20 2025-11-18 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
80,647 +17.6%
230.72
US$4,110,547 		80,647 +17.6% 230.72 US$4,110,547
2025-08-12 2025-08-08 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
67,223 -47.3%
143.50
US$1,755,500 		67,223 -47.3% 143.50 US$1,755,500
2023-12-27 2023-12-22 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
96,525 -36.5%
162.37
US$3,381,128 		96,525 -36.5% 162.37 US$3,381,128
2023-12-19 2023-12-18 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
10,000 +12.7%
1.84
US$18,442 		10,000 +12.7% 1.84 US$18,442
2023-11-27 2023-11-22 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
20,000 +34.0%
2.03
US$40,690 		20,000 +34.0% 2.03 US$40,690
2023-11-20 2023-11-20 B Purchase
3.1
Fishman Corey N.

Chief Executive Officer

Executive Director
10,000 +22.5%
1.59
US$15,863 		10,000 +22.5% 1.59 US$15,863
2022-12-05 2022-12-02 S Sale
3.2
Puttagunta Sailaja

Chief Medical Officer

Officer
3,365 -40.4%
1.32
US$4,442 		3,365 -40.4% 1.32 US$4,442
2022-09-20 2022-09-20 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
7,246 -100.0%
1.78
US$12,910 		7,246 -100.0% 1.78 US$12,910
2022-09-20 2022-09-19 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -67.4%
1.77
US$26,478 		15,000 -67.4% 1.77 US$26,478
2022-09-20 2022-09-16 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -40.3%
1.90
US$28,542 		15,000 -40.3% 1.90 US$28,542
2022-09-15 2022-09-15 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -28.7%
2.02
US$30,272 		15,000 -28.7% 2.02 US$30,272
2022-09-15 2022-09-14 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -22.3%
2.10
US$31,456 		15,000 -22.3% 2.10 US$31,456
2022-09-15 2022-09-13 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -18.2%
2.14
US$32,118 		15,000 -18.2% 2.14 US$32,118
2022-09-12 2022-09-12 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -15.4%
2.31
US$34,608 		15,000 -15.4% 2.31 US$34,608
2022-09-12 2022-09-09 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
15,000 -13.4%
2.32
US$34,730 		15,000 -13.4% 2.32 US$34,730
2022-09-12 2022-09-08 S Sale
3.6
Ahrens Brenton Karl
Non-Executive Director
3,298 -2.9%
2.26
US$7,465 		3,298 -2.9% 2.26 US$7,465
2022-09-09 2022-09-07 B Purchase
2.7
Dunne Michael W.
Non-Executive Director
10,000 +39.1%
2.22
US$22,200 		10,000 +39.1% 2.22 US$22,200
2022-03-15 2022-03-14 S Sale
3.3
Matthews Judith M.

Chief Financial Officer

Officer
47,132 -36.6%
0.38
US$17,910 		47,132 -36.6% 0.38 US$17,910
2021-02-12 2021-02-12 S Sale
2.8
DENNER ALEXANDER J
Large shareholder
10,619,949 -100.0%
2.27
US$24,107,284 		10,619,949 -100.0% 2.27 US$24,107,284
2021-02-12 2021-02-11 S Sale
2.8
DENNER ALEXANDER J
Large shareholder
10,000,000 -48.5%
2.59
US$25,900,000 		10,000,000 -48.5% 2.59 US$25,900,000
2021-01-27 2021-01-26 S Sale
3.1
Fishman Corey N.

President & CEO

Executive Director
85,445 -21.0%
1.73
US$147,820 		85,445 -21.0% 1.73 US$147,820
2021-01-27 2021-01-26 S Sale
2.7
Dunne Michael W.
Non-Executive Director
33,143 -11.4%
1.73
US$57,337 		33,143 -11.4% 1.73 US$57,337
2021-01-27 2021-01-26 S Sale
3.3
Matthews Judith M.

Chief Financial Officer

Officer
33,868 -54.2%
1.73
US$58,592 		33,868 -54.2% 1.73 US$58,592
2020-10-28 2020-10-27 B Purchase
2.7
Dunne Michael W.

Chief Scientific Officer

Officer
61,540
0.00
US$0 		61,540 0.00 US$0
2020-10-02 2020-09-30 PlS Planned sale
3.3
Matthews Judith M.

Chief Financial Officer

Officer
56,130 -100.0%
1.64
US$92,053 		56,130 -100.0% 1.64 US$92,053
2020-06-03 2020-06-02 S Sale
3.6
Sofinnova Venture Partners IX, L.P.
Large shareholder
400,000 -24.6%
1.61
US$642,960 		400,000 -24.6% 1.61 US$642,960
2020-06-03 2020-06-01 S Sale
3.6
Sofinnova Venture Partners IX, L.P.
Large shareholder
100,000 -5.8%
1.69
US$169,120 		100,000 -5.8% 1.69 US$169,120
2018-12-04 2018-11-30 B Purchase Kelly David George Non-Executive Director
10,000 +104.7%
6.29
US$62,887 		10,000 +104.7% 6.29 US$62,887
2018-11-01 2018-10-30 B Purchase Chin Mark Non-Executive Director
58,000 +5.6%
6.10
US$353,800 		58,000 +5.6% 6.10 US$353,800
2018-09-06 2018-09-04 B Purchase Dunne Michael W.

Chief Scientific Officer

Officer
500 +0.3%
10.00
US$5,000 		500 +0.3% 10.00 US$5,000
2018-08-28 2018-08-27 B Purchase Dunne Michael W.

Chief Scientific Officer

Officer
500 +0.3%
10.00
US$5,000 		500 +0.3% 10.00 US$5,000
2018-08-28 2018-08-24 B Purchase Dunne Michael W.

Chief Scientific Officer

Officer
500 +0.3%
10.00
US$5,000 		500 +0.3% 10.00 US$5,000
2018-08-27 2018-08-23 B Purchase Edick Paul R Non-Executive Director
500 +2.0%
10.44
US$5,219 		500 +2.0% 10.44 US$5,219
2018-08-21 2018-08-17 B Purchase Fishman Corey N.

President & CEO

Executive Director
2,000 +0.8%
8.73
US$17,466 		2,000 +0.8% 8.73 US$17,466
2018-06-01 2018-05-30 B Purchase Chin Mark Non-Executive Director
337,606 +48.6%
13.00
US$4,388,878 		337,606 +48.6% 13.00 US$4,388,878
2018-05-31 2018-05-30 B Purchase Lathi Vijay K Large shareholder
384,615 +inf%
13.00
US$4,999,995 		384,615 +inf% 13.00 US$4,999,995
2018-05-31 2018-05-30 B Purchase Lathi Vijay K Large shareholder
278,062 +35.0%
13.00
US$3,614,806 		278,062 +35.0% 13.00 US$3,614,806
2018-05-31 2018-05-30 B Purchase HUNT RONALD Non-Executive Director Large shareholder
384,615 +inf%
13.00
US$4,999,995 		384,615 +inf% 13.00 US$4,999,995
2018-05-31 2018-05-30 B Purchase HUNT RONALD Non-Executive Director Large shareholder
278,062 +35.0%
13.00
US$3,614,806 		278,062 +35.0% 13.00 US$3,614,806
2018-05-30 2018-05-30 B Purchase Fishman Corey N.

President & CEO

Executive Director
3,000 +1.3%
13.00
US$39,000 		3,000 +1.3% 13.00 US$39,000
2018-05-30 2018-05-30 B Purchase CANAAN X L.P. Non-Executive Director Large shareholder
506,656 +41.3%
13.00
US$6,586,528 		506,656 +41.3% 13.00 US$6,586,528
2018-05-30 2018-05-30 B Purchase Matthews Judith M.

Chief Financial Officer

Officer
4,000 +7.7%
13.00
US$52,000 		4,000 +7.7% 13.00 US$52,000
2018-05-30 2018-05-30 B Purchase Ahrens Brenton Karl Non-Executive Director
506,656 +41.3%
13.00
US$6,586,528 		506,656 +41.3% 13.00 US$6,586,528
2018-05-30 2018-05-30 B Purchase Malik Shahzad Non-Executive Director
228,840 +37.5%
13.00
US$2,974,920 		228,840 +37.5% 13.00 US$2,974,920
2018-05-30 2018-05-30 B Purchase Malik Shahzad Non-Executive Director
8,144 +37.5%
13.00
US$105,872 		8,144 +37.5% 13.00 US$105,872
2018-05-30 2018-05-30 B Purchase Heron Patrick J Non-Executive Director Large shareholder
101,150 +42.1%
13.00
US$1,314,950 		101,150 +42.1% 13.00 US$1,314,950
2018-05-30 2018-05-30 B Purchase Heron Patrick J Non-Executive Director Large shareholder
354,949 +42.1%
13.00
US$4,614,337 		354,949 +42.1% 13.00 US$4,614,337
2018-05-30 2018-05-30 B Purchase Dunne Michael W.

Chief Scientific Officer

Officer
2,000 +1.4%
13.00
US$26,000 		2,000 +1.4% 13.00 US$26,000
2018-05-30 2018-05-30 B Purchase HEALY JAMES Non-Executive Director Large shareholder
500,000 +40.8%
13.00
US$6,500,000 		500,000 +40.8% 13.00 US$6,500,000
2018-05-30 2018-05-30 B Purchase Sofinnova Venture Partners IX, L.P. Large shareholder
500,000 +40.8%
13.00
US$6,500,000 		500,000 +40.8% 13.00 US$6,500,000
Explore more

More insider trading research around Iterum Therapeutics PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America